Filing Flows › Conmed (CNMD) › R&D spending
Conmed (CNMD) R&D spending by quarter
Conmed's R&D spending was $15.6M in Q3 2026 (third quarter 2026), +0.6% from Q2 2026. Over the last 7 quarters it ranged from $12.9M (Q1 2025) to $16.3M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $15.6M | +0.6% | +12% |
| Q2 2026 | $15.5M | -5% | +10% |
| Q1 2026 | $16.3M | +10% | +26% |
| Q4 2025 | $14.9M | +7% | — |
| Q3 2025 | $13.9M | -2% | — |
| Q2 2025 | $14.1M | +9% | — |
| Q1 2025 | $12.9M | — | — |
Q3 2026 at a glance
Conmed, Q3 2026: revenue $336M (-0.7% year over year), operating margin 11.1%, net earnings $19.8M, operating cash flow $49.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Conmed's R&D spending?
Conmed's R&D spending was $15.6M in Q3 2026 (third quarter 2026), +0.6% from Q2 2026.
How has Conmed's R&D spending changed?
Over the last 7 quarters it ranged from $12.9M (Q1 2025) to $16.3M (Q1 2026).